Teclistamab (Tecvayli)

Teclistamab (Tecvayli) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engaging antibody for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication was approved under accelerated approval based on response rate,and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Teclistamab binds to the CD3 receptor expressed on the surface of T-cells and BCMA expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, teclistamab activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells. Teclistamab (Tecvayli) has boxed warnings due to cytokine release syndrome (CRS) and neurologic toxicity. Tecvayli is available only through a restricted program called the TECVAYLI and TALVEY Risk Evaluation and Mitigation Strategy (REMS). <a id="